Breakthrough HAE treatment enters final Long-Term testing phase

NCT ID NCT07428499

Summary

This study continues testing ADX-324, an experimental treatment for hereditary angioedema (HAE), to see how safe and effective it is over a longer period. It's for people who already completed the main trial and have HAE types 1 or 2. Researchers will track side effects, count how many HAE attacks participants have, and measure quality of life.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HAE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.